Literature DB >> 19410272

Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.

Kaustuv Banerjee1, Sofija Andjelic, Per Johan Klasse, Yun Kang, Rogier W Sanders, Elizabeth Michael, Robert J Durso, Thomas J Ketas, William C Olson, John P Moore.   

Abstract

The Env glycoproteins gp120 and gp41 are used in humoral immunity-based vaccines against human immunodeficiency virus (HIV-1) infection. One among many obstacles to such a vaccine is the structural defenses of Env glycoproteins that limit their immunogenicity. For example, gp120 mannose residues can induce immunosuppressive responses in vitro, including IL-10 expression, via mannose C-type lectin receptors on antigen-presenting cells. Here, we have investigated whether mannose removal alters gp120 immunogenicity in mice. Administering demannosylated gp120 (D-gp120) in the T(H)2-skewing adjuvant Alum induced approximately 50-fold higher titers of anti-gp120 IgG, compared to unmodified gp120. While the IgG subclass profile was predominantly T(H)2-associated IgG1, Abs of the T(H)1-associated IgG2a and IgG3 subclasses were also detectable in D-gp120 recipients. Immunizing with D-gp120 also improved T-cell responses. Giving an IL-10 receptor blocking MAb together with unmodified gp120 in Alum increased the anti-gp120 IgG titer, implicating IL-10 as a possible mediator of auto-suppressive responses to gp120.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19410272      PMCID: PMC2743082          DOI: 10.1016/j.virol.2009.04.001

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  77 in total

1.  Increase in plasma IL-10 levels and rapid loss of CD4+ T cells among HIV-infected individuals in south India.

Authors:  P Srikanth; R C Castillo; G Sridharan; T J John; A Zachariah; D Mathai; D H Schwartz
Journal:  Int J STD AIDS       Date:  2000-01       Impact factor: 1.359

Review 2.  Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells.

Authors:  H L Weiner
Journal:  Microbes Infect       Date:  2001-09       Impact factor: 2.700

3.  Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.

Authors:  Laura Bungener; Felix Geeraedts; Wouter Ter Veer; Jeroen Medema; Jan Wilschut; Anke Huckriede
Journal:  Vaccine       Date:  2008-03-18       Impact factor: 3.641

Review 4.  Toward an AIDS vaccine.

Authors:  Bruce D Walker; Dennis R Burton
Journal:  Science       Date:  2008-05-09       Impact factor: 47.728

Review 5.  Interleukin-10 and the interleukin-10 receptor.

Authors:  K W Moore; R de Waal Malefyt; R L Coffman; A O'Garra
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

Review 6.  Cell surface receptors, virus entry and tropism of primate lentiviruses.

Authors:  Paul R Clapham; Áine McKnight
Journal:  J Gen Virol       Date:  2002-08       Impact factor: 3.891

7.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

Authors:  Rogier W Sanders; Miro Venturi; Linnea Schiffner; Roopa Kalyanaraman; Hermann Katinger; Kenneth O Lloyd; Peter D Kwong; John P Moore
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Different mechanisms are utilized by HIV-1 Nef and staphylococcal enterotoxin A to control and regulate interleukin-10 production.

Authors:  Nutthapong Tangsinmankong; Noorbibi K Day; Robert A Good; Soichi Haraguchi
Journal:  Immunol Lett       Date:  2002-11-01       Impact factor: 3.685

10.  Mycobacteria target DC-SIGN to suppress dendritic cell function.

Authors:  Teunis B H Geijtenbeek; Sandra J Van Vliet; Estella A Koppel; Marta Sanchez-Hernandez; Christine M J E Vandenbroucke-Grauls; Ben Appelmelk; Yvette Van Kooyk
Journal:  J Exp Med       Date:  2003-01-06       Impact factor: 14.307

View more
  35 in total

1.  Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies.

Authors:  Sanchari Bhattacharyya; Roshan Elizabeth Rajan; Yalla Swarupa; Ujjwal Rathore; Anjali Verma; Ranga Udaykumar; Raghavan Varadarajan
Journal:  J Biol Chem       Date:  2010-06-17       Impact factor: 5.157

2.  HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation.

Authors:  Thijs van Montfort; Dirk Eggink; Maikel Boot; Michael Tuen; Catarina E Hioe; Ben Berkhout; Rogier W Sanders
Journal:  J Immunol       Date:  2011-09-28       Impact factor: 5.422

3.  Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization.

Authors:  James M Binley; Yih-En Andrew Ban; Emma T Crooks; Dirk Eggink; Keiko Osawa; William R Schief; Rogier W Sanders
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

4.  Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice.

Authors:  Dapeng Li; Markus von Schaewen; Xuesong Wang; Wanyin Tao; Yunfang Zhang; Li Li; Brigitte Heller; Gabriela Hrebikova; Qiang Deng; Alexander Ploss; Jin Zhong; Zhong Huang
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

Review 5.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

6.  Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.

Authors:  Rebecca L R Powell; Maxim Totrov; Vincenza Itri; Xiaomei Liu; Alisa Fox; Susan Zolla-Pazner
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

Review 7.  Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?

Authors:  P J Klasse; Gabriel Ozorowski; Rogier W Sanders; John P Moore
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

8.  IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.

Authors:  Kaustuv Banerjee; P J Klasse; Rogier W Sanders; Florencia Pereyra; Elizabeth Michael; Min Lu; Bruce D Walker; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2010-04       Impact factor: 2.205

9.  Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies.

Authors:  Jinsong Zhang; S Munir Alam; Hilary Bouton-Verville; Yao Chen; Amanda Newman; Shelley Stewart; Frederick H Jaeger; David C Montefiori; S Moses Dennison; Barton F Haynes; Laurent Verkoczy
Journal:  J Immunol       Date:  2014-01-24       Impact factor: 5.422

10.  Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin.

Authors:  Robert P de Vries; Cornelis H Smit; Erwin de Bruin; Alan Rigter; Erik de Vries; Lisette A H M Cornelissen; Dirk Eggink; Nancy P Y Chung; John P Moore; Rogier W Sanders; Cornelis H Hokke; Marion Koopmans; Peter J M Rottier; Cornelis A M de Haan
Journal:  J Virol       Date:  2012-08-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.